{"id":1388,"date":"2025-11-14T10:43:25","date_gmt":"2025-11-14T10:43:25","guid":{"rendered":"https:\/\/admit-therapeutics.com\/?p=1388"},"modified":"2025-12-05T18:49:19","modified_gmt":"2025-12-05T18:49:19","slug":"admit-therapeutics-presents-innovation-in-seville-the-map-ad-test-and-new-data-on-alzheimers-prediction","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-innovation-in-seville-the-map-ad-test-and-new-data-on-alzheimers-prediction\/","title":{"rendered":"ADmit Therapeutics Presents Innovation in Seville: The MAP-AD\u00ae\u00a0Test and New Data on Alzheimer&#8217;s Prediction"},"content":{"rendered":"\n<p><strong>The company will attend the SEN Annual Meeting with its MAP-AD<sup>\u00ae<\/sup>&nbsp;test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer&#8217;s disease dementia prognosis.<\/strong><\/p>\n\n\n\n<p>Barcelona (Spain), November 14, 2025\u00a0\u2013 ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming\u00a0<strong>Annual Meeting of the Spanish Society of Neurology (SEN)<\/strong>, to be held in Seville. The company will use the event to showcase the latest developments in the prediction and prognosis of Alzheimer&#8217;s Disease dementia.<\/p>\n\n\n\n<p><strong>The MAP-AD<sup>\u00ae<\/sup> Test: The Focus of Innovation<\/strong><\/p>\n\n\n\n<p>The most significant announcement is the presentation of the&nbsp;<strong>MAP-AD\u00ae test<\/strong>, recently certified with the&nbsp;<strong>CE-IVDR mark<\/strong>, a milestone that validates its quality and safety for diagnostic use within the European Union. This test is the central focus of ADmit Therapeutics&#8217; activities at the meeting.<\/p>\n\n\n\n<p>The company will host two informative sessions (<em>\u00c1goras<\/em>) exclusively dedicated to this test at the event&#8217;s Technological Hub:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Wednesday, November 19, 2025:<\/strong>&nbsp;from 6:00 PM to 7:00 PM.<\/li>\n\n\n\n<li><strong>Thursday, November 20, 2025:<\/strong>&nbsp;from 10:30 AM to 11:30 AM.<\/li>\n<\/ul>\n\n\n\n<p><strong>New Clinical Data at the Conference<\/strong><\/p>\n\n\n\n<p>In addition to the stand sessions, ADmit Therapeutics will present new validation data in the&nbsp;<strong>Behavior and Dementia<\/strong>&nbsp;section. The presentation is titled:<\/p>\n\n\n\n<p><strong>\u201cPrediction of progression to dementia in Alzheimer&#8217;s disease: Clinical validation of a blood test independent of amyloid and tau pathology\u201d<\/strong><\/p>\n\n\n\n<p>This session will take place on&nbsp;<strong>November 19 at 8:30 PM<\/strong>&nbsp;at the Barcel\u00f3 Sevilla Convention Center, Atrio III (Screen 8).<\/p>\n\n\n\n<p><strong>Visit Our Stand and Meet the Team<\/strong><\/p>\n\n\n\n<p>ADmit Therapeutics will welcome visitors at its stand, located in the Technological Hub, on&nbsp;<strong>November 19, 20, and 21<\/strong>.<\/p>\n\n\n\n<p>Our Project Manager, <strong>Carla Trapero<\/strong>, and&nbsp;Business Development Manager, <strong>Miguel Viribay<\/strong>, will be present and available to discuss innovations and the future of early Alzheimer&#8217;s Disease diagnosis.<\/p>\n\n\n\n<p>The company invites all attendees to visit its space to learn firsthand about the solutions that are redefining the prognosis of this disease.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"400\" height=\"324\" src=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/11\/SEN.jpg\" alt=\"\" class=\"wp-image-1390\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/11\/SEN.jpg 400w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/11\/SEN-300x243.jpg 300w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The company will attend the SEN Annual Meeting with its MAP-AD\u00ae&nbsp;test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer&#8217;s disease dementia prognosis. Barcelona (Spain), November 14, 2025\u00a0\u2013 ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming\u00a0Annual Meeting of the Spanish Society of Neurology [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1388","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=1388"}],"version-history":[{"count":3,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1388\/revisions"}],"predecessor-version":[{"id":1414,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1388\/revisions\/1414"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=1388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=1388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=1388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}